Switch theme
Sign up to access all valuation multiples
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicine, liquid tonic, drink, and healthy food. The company has three segments: MLM (Multi-Level Marketing) is a direct seller of Pro-partner Inc, including the company’s development and manufacturing products for Pro-partner Inc, Distributors segment includes the company’s self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
1969
565
Last FY Revenue $386M
Last FY EBITDA $110M
$502M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Grape King Bio achieved revenue of $386M and an EBITDA of $110M.
Grape King Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Grape King Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $386M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $299M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 78% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $110M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 29% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $86.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $55.6M | XXX | $50.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Grape King Bio's stock price is TWD 123 (or $4).
Grape King Bio has current market cap of TWD 18.2B (or $630M), and EV of TWD 14.5B (or $502M).
See Grape King Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $502M | $630M | XXX | XXX | XXX | XXX | $0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Grape King Bio has market cap of $630M and EV of $502M.
Grape King Bio's trades at 1.3x EV/Revenue multiple, and 4.6x EV/EBITDA.
Equity research analysts estimate Grape King Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grape King Bio has a P/E ratio of 11.3x.
See valuation multiples for Grape King Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $630M | XXX | $630M | XXX | XXX | XXX |
| EV (current) | $502M | XXX | $502M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 5.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.3x | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 11.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGrape King Bio's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
Grape King Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Grape King Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Grape King Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grape King Bio acquired XXX companies to date.
Last acquisition by Grape King Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Grape King Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Grape King Bio founded? | Grape King Bio was founded in 1969. |
| Where is Grape King Bio headquartered? | Grape King Bio is headquartered in Taiwan. |
| How many employees does Grape King Bio have? | As of today, Grape King Bio has 565 employees. |
| Is Grape King Bio publicy listed? | Yes, Grape King Bio is a public company listed on TAI. |
| What is the stock symbol of Grape King Bio? | Grape King Bio trades under 1707 ticker. |
| When did Grape King Bio go public? | Grape King Bio went public in 1982. |
| Who are competitors of Grape King Bio? | Similar companies to Grape King Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Grape King Bio? | Grape King Bio's current market cap is $630M |
| Is Grape King Bio profitable? | Yes, Grape King Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
